Time to refocus on HSV interventions for HIV prevention?

Journal of Infectious Diseases

Volumn 204, Issue 12, 2011, Pages 1822-1826

  Tanton, Clare ^a   Abu Raddad, Laith J ^b   Weiss, Helen A ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; RNA DIRECTED DNA POLYMERASE; VALACICLOVIR; VIRUS RNA;

ANTIVIRAL SUSCEPTIBILITY; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; ETHNIC DIFFERENCE; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; NONHUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEXUAL BEHAVIOR; VIRUS LOAD; VIRUS TRANSMISSION;

ACYCLOVIR; ANTIVIRAL AGENTS; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; VALINE;

EID: 81055124981     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir653     Document Type: Note

References (36)

1. Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared to standard dose acyclovir among HIV-1/HSV-2 co-infected persons: a randomized, cross-over trial. J Infect Dis 2011; 204:1912-7.
2. World Health Organization. Herpes simplex virus type 2: programmatic and research priorities in developing countries (Report of a WHO/UNAIDS/LSHTM Workshop; London 14-16 February 2001). Geneva: WHO/UNAIDS, 2001. http://www.who.int/hiv/pub/sti/en/hiv-aids-2001.05.pdf. Accessed 30 September 2011.
3. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-8.
4. Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008; 84:548-53.
5. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461-9.
6. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV-and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49: 77-83.
7. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-9. (Pubitemid 46294611)
8. Tanton C, Weiss HA, Rusizoka M, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. J Infect Dis 2010; 201: 1285-97.
9. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500-8. (Pubitemid 351411987)
10. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-39.
11. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375: 824-33.
12. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-9.
13. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358: 1560-71. (Pubitemid 351519816)
14. Lu Y, Hendrix C, Celum C, et al. Acyclovir achieves lower concentration in African HIV-, HSV21 women compared to non-African populations, possibly explaining lower herpes suppression. Sex Transm Infect 2011; 87(Suppl-1): A79.
15. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4: 260-70.
16. McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283: 31289-93.
17. Lisco A, Vanpouille C, Margolis L. A missed point in deciphering the viral synergy between herpes simplex virus and HIV. Lancet Infect Dis 2009; 9:522-3.
18. Perti T, Baeten JM, Johnston C, et al. Highdose valacyclovir decreases plasma HIV-1 levels more than standard dose acyclovir in HIV-1, HSV-2 positive persons: a randomised, crossover trial. Sex Transm Infect 2011; 87(Suppl 1):A350.
19. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83. (Pubitemid 41818117)
20. Orroth KK, White RG, Korenromp EL, et al. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: simulation results. Sex Transm Dis 2006; 33:536-44. (Pubitemid 44318977)
21. Freeman EE, Orroth KK, White RG, et al. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 2007; 83: i17-24. (Pubitemid 47242468)
22. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008; 3: e2230.
23. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New Engl J Med 2000; 342:921-9. (Pubitemid 30177052)
24. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
25. Wiktor SZ, Ekpini E, Karon JM, et al. Shortcourse oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353:781-5. (Pubitemid 29110402)
26. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314:1603-6. (Pubitemid 44907155)
27. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 5:e12598.
28. Baggaley RF, Griffin JT, Chapman R, et al. Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. AIDS 2009; 23:1005-13.
29. Abu-Raddad LJ, Longini IM Jr. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 2008; 22: 1055-61. (Pubitemid 351769744)
30. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179-85.
31. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55: 459-72.
32. Watson-Jones D, Wald A, Celum C, et al. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol 2010; 48: 3496-503.
33. Kohler PK, Chung MH, McGrath CJ, Benki-Nugent SF, Thiga JW, John-Stewart GC. Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya. AIDS 2011; 25:1657-1.
34. Tchesnokov EP, Obikhod A, Massud I, et al. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase. J Biol Chem 2009; 284:21496-504.
35. Baeten JM, Lingappa J, Beck I, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis 2011; 203:117-21.
36. LeGoff J, Tanton C, Delaugerre C, et al. No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons. AIDS 2010; 24:2595-6.